Tevogen Bio To Discusses Its Genetically Unmodified T Cell Technology For The Treatment of Infectious Diseases, Cancers, And Neurological Disorders With Nasdaq's Kristina Ayanian
Tevogen Bio To Discusses Its Genetically Unmodified T Cell Technology For The Treatment of Infectious Diseases, Cancers, And Neurological Disorders With Nasdaq's Kristina Ayanian
Tevogen Bio将与纳斯达克的Kristina Ayanian讨论其用于治疗传染病、癌症和神经系统疾病的基因未经修改的T细胞技术。
- Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applications
- Tevogen's ExacTcell platform is designed to address current cost, and patient accessibility challenges
- ExacTcell's first product consists of single HLA restricted, off-the-shelf, genetically unmodified T cells
- Broad application potential spanning cancer, infectious diseases, and neurological disorders
- ExacTcell platform produced hundreds of doses from a single donor, facilitating cost reduction
- Flomenberg博士和Grosso博士是T细胞生物学及其临床应用的领先专家。
- Tevogen的ExacTcell平台旨在解决当前成本和病人可及性方面的挑战。
- ExacTcell的第一个产品包括单个HLA限制、非基因修饰的电芯。
- 广泛适用于癌症、传染病和神经系统疾病治疗，具有大量的应用潜力。
- ExacTcell平台可从单个供体中生产数百剂次，有助于降低成本。
WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise of T cell therapy and Tevogen's mission to make it mainstream on Nasdaq's broadcast, Live From MarketSite with Kristina Ayanian.
2024年7月10日，新泽西州沃伦（GLOBE NEWSWIRE）——Tevogen Bio Holding Inc.（“Tevogen”或“Tevogen Bio”）（纳斯达克代码：TVGN），一家临床阶段的特殊免疫治疗生物技术先驱，正在开发用于肿瘤学、神经学和病毒学领域的非基因修饰的即插即用电芯治疗方案。Flomenberg博士和Lori Grosso博士在纳斯达克的广播节目“Live From MarketSite with Kristina Ayanian”中讨论了电芯治疗的前景和Tevogen将其打造成主流的使命。